InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,712.69
(
-0.28%
)
US TECH 100
19,428.79
(
-0.35%
)
Dow Jones
41,794.60
(
-0.61%
)
Brent Oil
74.97
(
-0.20%
)
Bitcoin
67,874.72
(
0.08%
)

Replies to post #360 on SciSparc Ltd (SPRC)

Replies to #360 on SciSparc Ltd (SPRC)
icon url

tw0122

05/02/23 7:57 AM

#361 RE: subslover #360

Not holding gains”As in this morning on news :SciSparc believes that the current pharmacological treatment of agitation in AD has an unsatisfactory benefit-to-risk ratio. All used drugs to treat AD are off label as evidenced by the fact that no FDA approved drug to treat agitation in AD exists. Hence, SciSparc believes the pharmacological treatment of agitation in AD is unequivocally, an unmet need.